Jesper Brandgaard joined Novo Nordisk in 1999 as senior vice president of Corporate Finance and was appointed executive vice president and chief financial officer in November 2000. As chief financial officer, Mr Brandgaard was responsible for a number of functions including finance, legal, procurement and investor relations. In 2017, Mr Brandgaard assumed additional responsibility for the Biopharm activities. In February 2018, Mr. Brandgaard changed his area of responsibility and became executive vice president of Biopharm and Global Legal & Patents.
Mr Brandgaard serves as chair of the board of SimCorp A/S, Denmark, and is vice chair of the board of Chr. Hansen Holding A/S, Denmark, where he is also member of the nomination and audit committee. Mr Brandgaard is also member of the foundation council for the Novo Nordisk Haemophilia Foundation.
Mr Brandgaard has an MSc in Economics and Auditing from 1990 as well as an MBA from 1995, both from the Copenhagen Business School, Denmark.
Mr Brandgaard is a Danish national, born October 1963.